Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19.

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE237180 | GEO | 2024/05/05

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

Project description:Dexamethasone is the standard of care for critically ill patients with COVID-19, but its immunological effects in this setting and the mechanisms by which it decreases mortality are not understood. We performed bulk and single-cell RNA sequencing of the lower respiratory tract and blood, and plasma cytokine profiling to study the effect of dexamethasone on systemic and pulmonary immune cells. We find signatures of decreased viral injury, antigen presentation, and T cell recruitment in patients treated with dexamethasone. We identify compartment- and cell- specific differences in the effect of dexamethasone in patients with severe COVID that are reproducible in publicly available datasets. Our results highlight the importance of studying compartmentalized inflammation in critically ill patients.

2024-05-05 | GSE237109 | GEO

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

2024-05-05 | GSE236030 | GEO

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

Project description:Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

| PRJNA988459 | ENA

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19.

Project description:Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19.

| PRJNA994127 | ENA

Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

Project description:Distinct pulmonary and systemic effects of dexamethasone in severe COVID-19

| PRJNA993792 | ENA

Distinct B cell repertoires characterize patients with mild and severe COVID-19

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-04-26 | GSE164381 | GEO

COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes

Project description:This SuperSeries is composed of the SubSeries listed below.

2023-12-02 | GSE248778 | GEO

Effects of Dexamethasone in COVID-19 patients

Project description:Dexamethasone improves the survival of COVID-19 patients in need of supplemental oxygen therapy. Hospitalized COVID-19 patients eligible for dexamethasone therapy were recruited from the general care ward in several centers in Greece and the Netherlands and whole blood transcriptomic analysis was performed before and after starting dexamethasone treatment. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy individuals and COVID-19 patients and stimulated with inactivated SARS-CoV-2 ex vivo in the presence or absence of dexamethasone and their transcriptome was assessed.

2023-07-26 | GSE227585 | GEO

Dexamethasone modulates immature neutrophils and interferon programming in severe COVID-19

Project description:While critical for host defense, innate immune cells are also pathologic drivers of acute respiratory distress syndrome (ARDS). Innate immune dynamics during COVID-19 ARDS, compared to ARDS from other respiratory pathogens, is unclear. Moreover, mechanisms underlying beneficial effects of dexamethasone during severe COVID-19 remain elusive. Using scRNA-seq and plasma proteomics, we discovered that compared to bacterial ARDS, COVID-19 was associated with expansion of distinct neutrophil states characterized by interferon (IFN) and prostaglandin (PG) signalling. Dexamethasone during severe COVID-19 depleted circulating neutrophils, altered IFNactive neutrophils, downregulated interferon-stimulated gene, and activated IL1R2+ve neutrophils. Dexamethasone also expanded immunosuppressive immature neutrophils and remodeled cellular interactions by changing neutrophils from information receivers into information providers. Male patients had higher proportions of IFNactive neutrophils, preferential steroid-induced immature neutrophil expansion, and possibly different effects on outcome. Our single-cell atlas (www.biernaskielab.ca/COVID_neutrophil) defines COVID-19-enriched neutrophil states and molecular mechanisms of dexamethasone action to develop targeted immunotherapies for severe COVID-19.

2021-10-05 | GSE157789 | GEO

Functional reprogramming of monocytes in acute and convalescent severe COVID-19 patients

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-04-01 | GSE198257 | GEO